Navigation Links
China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
Date:11/7/2008

Total Current Assets 54,517,942 38,022,998

Non-current Assets:

Property and equipment, net of

accumulated depreciation of

$1,350,913 and $1,003,802,

respectively 2,619,965 2,625,216

Intangible assets, net of accumulated

amortization of $465,132 and

$221,715, respectively 2,432,253 2,063,252

Advances for purchases of

intangible assets 6,840,631 807,345

Deferred tax assets 413,890 187,509

Total Non-current Assets 12,306,739 5,683,322

TOTAL ASSETS $66,824,681 $43,706,320

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities:

Trade accounts payable $505,704 $297,299

Accrued expenses 47,450 261,301

Accrued taxes payable 946,948 311,009

Other payables 130,652 86,161

Advances from customers 674,135 261,583

Short-term notes payable -- 2,693,428

Total Current Liabilities 2,304,889 3,910,781

Research and development commitments 36,381 34,181

Total Liabilities 2,341,270 3,944,962

Stockholders' Equity:

Common stock, $0.001 par value,

60,000,000 shares authorized,

42,278,938 and 37,278,938 shares

issued and outstanding, respectively 42,279 37,279

Additional paid-in capital 21,062,586 11,678,606

Foreign currency translation

adjustment
'/>"/>

SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008
2. TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China
3. China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26
4. China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results
5. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
6. China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination
7. China Medical Technologies to Attend Credit Suisse Asian Healthcare Conference
8. China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions
9. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
10. China Sky One Medical, Inc. Receives Tax Refund
11. Mindray Medical to Exhibit New Products at 60th China International Medical Equipment Fair

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...Newswire/--XiotechCorporationtodayannouncedthatMas...000storagesystem,poweredbyIntelligentStorageElemen...eneeds,enablefuturegrowthanddeliversignificantcapi...r. ,, MasonGeneral,locatedinShelton,Wash.,wasra...ostWired-Rural"hospitalsin2008and2009foritssuperio...
(Date:11/23/2009)...e/--Thanksgivingweekendmarksthe36thannualStateFarm...representsthesportsmanshipandprideoftwoschoolsbuti...seinattendance. ,, ForthecrewofthenewU.S.CoastG...beforetheyworktotestandlaunchabrandnewshiptoprotec...yOfficerClaudeBovellandtherestofthecrewwillbeginte...
(Date:11/23/2009)...g flaxseed oil to the diet could reduce the risk o...with diabetes, according to a report to be publish...utrition and Public Health . , Mer Harvi and col... Egypt, have studied the effect of diabetes on bon...t might delay the onset of osteoporosis. The resea...
(Date:11/23/2009)...ly modified to produce bacterial proteins that are...ve been planted on more than 200 million hectares ... after the bacterium Bacillus thuringiensis , com...lowing farmers to save money and lessen environmen...wever, since insects can evolve resistance to toxi...
(Date:11/23/2009)...prove patient outcomes, research suggests , ...mbination drug therapy shows promise in treating p...rchers say. , The study from the Massachusetts ...t survival and tumor response in patients treated ...tor that has helped slow the growth of other cance...
Breaking Medicine News(10 mins):Health News:ISE Technology by Xiotech Helps Hospital Achieve Data Center Efficiency, Savings 2Health News:Nothing Is Like Being There 2Health News:Flaxseed oil and osteoporosis 2Health News:Insect resistance to Bt crops can be predicted, monitored and managed 2Health News:Combo Treatment Beneficial in Biliary-Tract Cancer Study 2
...cks colorectal cancer in mice , Non-steroidal an...d ibuprofen, and drugs that selectively target a p...ntestinal polyps, the precursors of colorectal can...ers, at Vanderbilt University School of Medicine, ...
...ct Judge Edward R. Korman ordered the FDA to make ...nor girls without a physician,s visit or prescript...so asked the FDA to consider making the drug avail...Council , s Senior Fellow for Regulatory Affairs, ...
...ream Flights Plus Card™ Sales to be Donated ... Opportunity to Receive Special Privileges and Ser...eatment for Pediatric Patients , ...Hospital. Through the use of the Dream Flights Plu...
...erve as Non-Executive Chairman of the Board - , ,...aq: GPRO ) announced today that its board of dir...chief executive officer (CEO), effective May 18, 2...fficer, will become president and CEO following th...
...maceuticals (Nasdaq: ENDP ) today announced the ...s Pharmaceuticals, Inc. Endo acquired Indevus thr...ch Indevus became a wholly owned subsidiary of End...are in cash and up to an additional $3.00 per shar...
...ince 1995 Targets Burgeoning German Demand for Hea...f., March 23 VeriFone Holdings, Inc. (NYSE: PAY...et growing demand in Germany for electronic health...of experience to meet the needs of healthcare orga...
Other Medicine News:Health News:JCI table of contents: March 23, 2009 2Health News:JCI table of contents: March 23, 2009 3Health News:JCI table of contents: March 23, 2009 4Health News:JCI table of contents: March 23, 2009 5Health News:JCI table of contents: March 23, 2009 6Health News:JCI table of contents: March 23, 2009 7Health News:JCI table of contents: March 23, 2009 8Health News:JCI table of contents: March 23, 2009 9Health News:Dream Flights Luxury Travel, Inc. and St. Jude Children's Research Hospital Join Forces to Find Cures and Save Children 2Health News:Dream Flights Luxury Travel, Inc. and St. Jude Children's Research Hospital Join Forces to Find Cures and Save Children 3Health News:Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer 2Health News:Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer 3Health News:Endo Pharmaceuticals Completes Acquisition of Indevus Pharmaceuticals 2Health News:VeriFone eHealth Initiative Extends German Market Presence 2Health News:VeriFone eHealth Initiative Extends German Market Presence 3
(Date:11/23/2009)...O,Calif.,Nov.23/PRNewswire-FirstCall/--Anesiva,Inc...r.DavidC.U,PrichardhaveagreedtojointheAnesivaboard...etweenAnesivaandArcionTherapeutics.Completionofthe...aceatthepreviouslyannouncedAnesiva2009AnnualMeetin...PSTat400OysterPoint,Suite107A,SouthSanFrancisco,Ca...
(Date:11/23/2009)...v.23/PRNewswire-FirstCall/--RaptorPharmaceuticalCo...nouncedresultsfromaPhase2bclinicaltrialofitspropri...mine")inpatientswithnephropathiccystinosis("cystin...ia,SanDiego("UCSD")GeneralClinicalResearchCenter,e...rmacodynamicsofasingledoseofDRCysteamineinninecyst...
(Date:11/23/2009)...AZER,Pa.,Nov.23/PRNewswire-FirstCall/--CeptionTher...ny,andCephalon,Inc.(Nasdaq: CEPH )todayannouncedre...reslizumab)asatreatmentforpediatriceosinophiliceso...mentintheco-primaryendpointsofchangesinesophageale...taindicatedthatpatientstreatedwithCINQUILshowedast...
Breaking Medicine Technology:Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4FDA Investigating Safety of Asthma Drug Xolair 51948 1FDA Investigating Safety of Asthma Drug Xolair 51948 2Does Your Child Need Vision Therapy 3F 51946 1Does Your Child Need Vision Therapy 3F 51946 2Does Your Child Need Vision Therapy 3F 51946 3Does Your Child Need Vision Therapy 3F 51946 4Cogdell Spencer ERDMAN 28SM 29 Announces the Signing of Contracts Totaling 2488 8 Million in Janesville Wisconsin 51944 1Cogdell Spencer ERDMAN 28SM 29 Announces the Signing of Contracts Totaling 2488 8 Million in Janesville Wisconsin 51944 2Cogdell Spencer ERDMAN 28SM 29 Announces the Signing of Contracts Totaling 2488 8 Million in Janesville Wisconsin 51944 3
... Pharmaceutical,Research & Development, L.L.C. (J&...nstrate doripenem (DORIBAX(TM), doripenem for inje...ore potent in vitro against certain,strains of Ent...lactamases,(ESBLs) than other commonly used carbap...cteria that can cause,infections of the digestive ...
...ments in Productivity, Quality of Life and Lessen...can College of Rheumatology (ACR) Annual Sc... PST -- UCB announced,today results from several P...tolizumab pegol) - the only PEGylated anti-TNF (Tu...ollege of Rheumatology (ACR) Annual Scientific,Mee...
Other Medicine Technology:New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10
TME 61 C
TME 60 S
...for traditional Lasik, Epi-Lasik and anterior and ...f rapidly changing technologies and applications i... remains a proven value, offering surgeons a platf... stay abreast of evolving technologies while prote...
...maging device that provides direct cross sectional...d subjective clinical evaluation in the detection ...mages and analyzes macular thickness, the retinal ...est technology for high resolution scans., ,S...
Medicine Products: